HEXAMETHYLMELAMINE IN OVARIAN-CANCER RESISTANT TO CYCLOPHOSPHAMIDE AND ADRIAMYCIN
- 1 January 1979
- journal article
- research article
- Vol. 63 (8) , 1375-1377
Abstract
Patients (34) resistant to cyclophosphamide and adriamycin received hexamethylmelamine at 1 of 2 dose regimens: 6 mg/kg per day orally for 21 days every 4 wk or 8 mg/kg per day orally for 21 days every 6 wk. Only 5 patients responded. Tolerance to the drug was, however, satisfactory; nausea, pyrosis and vomiting were the only frequent side effects. Myelosuppression occurred in only 1 case.This publication has 11 references indexed in Scilit:
- Adriamycin in ovarian cancer patients resistant to cyclophosphamidePublished by Elsevier ,1978
- Hexamethylmelamine in alkylating agent-resistant ovarian carcinomaCancer, 1978
- ADRIAMYCIN THERAPY FOR ADVANCED OVARIAN CARCINOMA RECURRENT AFTER CHEMOTHERAPY1978
- Phase II Evaluation of Cytembena (NSC-104801) in Patients With Advanced Ovarian Carcinoma Resistant to Alkylating Agents: Brief Communication 2JNCI Journal of the National Cancer Institute, 1977
- Melphalan vs polymelphalanum in ovarian cancer patients resistant to cyclophosphamide: A tentative statistical approach to balance risks and benefitsPublished by Elsevier ,1977
- CHEMOTHERAPY FOR MUSTARD-RESISTANT OVARIAN ADENOCARCINOMA - RANDOMIZED TRIAL OF CCNU AND METHYL-CCNU1977
- TREATMENT OF ADVANCED OVARIAN CARCINOMA WITH HIGH-DOSE CYCLOPHOSPHAMIDE AFTER FAILURE ON MELPHALAN1977
- Hexamethylmelamine.An evaluation of its role in the therapy of cancerCancer, 1976
- METHOTREXATE (NSC-740) WITH CITROVORUM FACTOR (NSC-3590) RESCUE, ALONE AND IN COMBINATION WITH CYCLOPHOSPHAMIDE (NSC-26271), IN OVARIAN CANCER1976
- PHASE-2 STUDY OF CIS-DICHLORODIAMMINEPLATINUM(II) (NSC-119875) IN ADVANCED ADENOCARCINOMA OF OVARY1976